v3.25.2
Intangible Assets
 9 Months Ended 12 Months Ended
Mar. 31, 2025
Jun. 30, 2024
Goodwill and Intangible Assets Disclosure [Abstract]    
Intangible Assets

  

4. Intangible Assets

 

The Company’s intangible assets consist of intellectual property acquired from LAT Pharma, Inc. and are amortized over their estimated useful lives.

 

The following is a summary of the Company’s intangible assets:

 

          
   March 31, 2025   June 30, 2024 
         
Intellectual Property  $2,293,770   $2,293,770 
Less: Accumulated Amortization   (2,058,085)   (1,886,052)
Intellectual Property, Net  $235,685   $407,718 

 

Amortization expense was $57,344 in each of the three-month periods ended March 31, 2025 and 2024. Amortization expense was $172,033 in each of the nine-month periods ended March 31, 2025 and 2024. The Company amortizes intellectual property over the expected original useful lives of 10 years.

 

Estimated future amortization expense is as follows: 

 

     
Year ending June 30, 2025 (Remaining 3 months)  $57,344 
2026   178,341 
   $235,685 

 

5. Intangible Assets

 

The Company’s intangible assets consist of intellectual property acquired from LAT Pharma, Inc. and are amortized over their estimated useful lives. The following is a summary of the intangible assets as of June 30, 2024 and 2023: 

        
   June 30, 2024   June 30, 2023 
         
Intellectual Property  $2,293,770   $2,293,770 
Less: Accumulated Amortization   (1,886,052)   (1,656,675)
Intellectual Property, Net  $407,718   $637,095 

 

Amortization expense amounted to $229,377 for each of the years ended June 30, 2024 and 2023, respectively. The Company amortizes intellectual property over the expected original useful lives of 10 years.

 

Estimated future amortization expense is as follows: 

     
Year ending June 30,    
2025  $229,377 
2026   178,341 
 Finite lived intangible assets, net  $407,718